Estado actual de la esclerosis múltiple en Colombia

Introduction: Two local epidemiological studies describe Colombia as low risk for multiple sclerosis (MS). New information systems, which allow for a more accurate approximation, are currently available. Objective: To estimate the national prevalence of MS, as well as by regions, and to analyze national drug costs. Materials and methods: We obtained data from the Individual Registry of Health care provision (RIPS), with the diagnosis code G35x for multiple sclerosis, taking the confirmed new and repeated diagnoses between 2009 and 2013, by gender, age group and geographical location. For the analysis of medications, we use the database SISMED 2014 searching for all drugs available in Colombia: interferon beta 1A, interferon beta 1B, glatiramer acetate, natalizumab, mitoxantrone and fingolimod. Results: According to the RIPS, 3,462 patients with diagnosis of MS contacted the health system in Colombia during the period 2009-2013. The national prevalence for the period was 7.52 / 100,000, with the highest figure in Bogota (16.25) with 1213 patients, followed by Quindio (13.03) and Risaralda (11.18). The largest proportion of patients were in the 50 to 54 years age group, and 70% were women. Additionally, in 2014 Colombia spent COP $ 86 billion pesos (43 million US dollars) for MS drugs, around US$12,500 per patient/year. Conclusion: Colombia is a country with intermediate risk for MS, a disease that implies a high direct cost for the health system.